U.K. Preclinical Cro Market Size & Outlook, 2026-2033
Global Market
Related Markets
UK preclinical cro market highlights
- The UK preclinical cro market generated a revenue of USD 521.2 million in 2025 and is expected to reach USD 1,027.9 million by 2033.
- The UK market is expected to grow at a CAGR of 9.2% from 2026 to 2033.
- In terms of segment, preclinical optimization, efficacy & pk/pd was the largest revenue generating development stage in 2025.
- Early CMC / Phase I–II Supply is the most lucrative development stage segment registering the fastest growth during the forecast period.
Preclinical cro market data book summary
| Market revenue in 2025 | USD 521.2 million |
| Market revenue in 2033 | USD 1,027.9 million |
| Growth rate | 9.2% (CAGR from 2026 to 2033) |
| Largest segment | Preclinical optimization, efficacy & pk/pd |
| Fastest growing segment | Early CMC / Phase I–II Supply |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Target Discovery, Preclinical Optimization, Efficacy & PK/PD, IND-Enabling Safety (GLP), Bioanalysis & Analytics, Early CMC / Phase I–II Supply |
| Key market players worldwide | Eurofins Scientific SE, Icon PLC, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Thermo Fisher Scientific Inc, Intertek Group PLC, Labcorp Holdings Inc, Crown Bioscience, SGA |
Other key industry trends
- In terms of revenue, UK accounted for 7.8% of the global preclinical cro market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Europe, UK preclinical cro market is projected to lead the regional market in terms of revenue in 2033.
- UK is the fastest growing regional market in Europe and is projected to reach USD 1,027.9 million by 2033.
The UK is a major hub for large pharmaceutical companies with a key focus on R&D activities and clinical trials to minimize the burden of various infectious diseases. According to gov.uk, in 2020, Life Science Competitiveness Indicators (LSCIs) presented the UK’s R&D expenditure, which showed that the government’s budget for health R&D was USD 3.44 billion (GBP 2. billion) in 2020, accounting for 0.12% of the country’s GDP.
Besides, industry conducted pharmaceutical R&D valued at over USD 6.37 billion (GBP 5 billion) in 2020. Increased healthcare R&D is one of the major factors responsible for the dominance of this country in the European preclinical trial outsourcing market. In March 2022, the UK government allocated over USD 347 million for healthcare research in order to improve the research activities in the country.
No credit card required*
Publish Date: Apr 23, 2026
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Preclinical CRO Market Scope
Preclinical CRO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Eurofins Scientific SE | View profile | 61,798 | 23 Val Fleuri, Luxembourg, Luxembourg, L-1526 | www.eurofins.com |
| Charles River Laboratories International Inc | View profile | 21,400 | 251 Ballardvale Street, Wilmington, MA, United States, 01887 | www.criver.com |
| Labcorp Holdings Inc | View profile | 67,000 | 358 South Main Street, Burlington, NC, United States, 27215 | www.labcorp.com |
| Icon PLC | View profile | 41,150 | South County Business Park, Leopardstown, Dublin, Ireland, D18 X5R3 | www.iconplc.com |
| Wuxi AppTec Co Ltd | View profile | 41,116 | 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, China, People's Republic of, 200131 | www.wuxiapptec.com |
| Medpace Holdings Inc | View profile | 5,800 | 5375 Medpace Way, Cincinnati, OH, United States, 45227 | www.medpace.com |
| Intertek Group PLC | View profile | 44,000 | 33 Cavendish Square, London, United Kingdom, W1G 0PS | www.intertek.com |
| Crown Bioscience | View profile | 251-500 | Santa Clara, California, United States, North America | www.crownbio.com |
| SGA | View profile | 11-50 | Las Condes, Region Metropolitana, Chile, South America | sgasa.cl |
U.K. Preclinical CRO Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Preclinical CRO Market Outlook will help companies and investors design strategic landscapes.
Preclinical Optimization, Efficacy & Pk/Pd was the largest segment with a revenue share of 33.29% in 2025.
Horizon Databook has segmented the U.K. preclinical cro market based on target discovery, preclinical optimization, efficacy & pk/pd, ind-enabling safety (glp), bioanalysis & analytics, early cmc / phase i–ii supply covering the revenue growth of each sub-segment from 2021 to 2033.
The UK is a major hub for large pharmaceutical companies with a key focus on R&D activities and clinical trials to minimize the burden of various infectious diseases. According to gov.uk, in 2020, Life Science Competitiveness Indicators (LSCIs) presented the UK’s R&D expenditure, which showed that the government’s budget for health R&D was USD 3.44 billion (GBP 2. billion) in 2020, accounting for 0.12% of the country’s GDP.
Besides, industry conducted pharmaceutical R&D valued at over USD 6.37 billion (GBP 5 billion) in 2020. Increased healthcare R&D is one of the major factors responsible for the dominance of this country in the European preclinical trial outsourcing market. In March 2022, the UK government allocated over USD 347 million for healthcare research in order to improve the research activities in the country.
- U.K. Preclinical Cro Market Development Stage Outlook (Revenue, USD Million , 2021-2033)
- Target Discovery
- Preclinical Optimization, Efficacy & PK/PD
- IND-Enabling Safety (GLP)
- Bioanalysis & Analytics
- Early CMC / Phase I–II Supply
- U.K. Preclinical Cro Market Indication Outlook (Revenue, USD Million , 2021-2033)
- Oncology
- CNS
- Infectious Diseases
- Cardiovascular Diseases
- Metabolic Disorders
- Rare Diseases
- Others
- U.K. Preclinical Cro Market End Use Outlook (Revenue, USD Million , 2021-2033)
- Pharmaceutical and Biopharmaceutical Companies
- Medical Device Companies
- Academic and Research Institutes
- Others
Reasons to subscribe to Preclinical CRO Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Preclinical CRO Market Outlook databook
- Our clientele includes a mix of Preclinical CRO Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.K. Preclinical CRO Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.K. Preclinical CRO Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
U.K. Preclinical Cro Market, 2021-2033 (US$M)
UK Development Stage - Preclinical Cro Market Statistics, 2025 - 2033 (US$M)
